SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 23, 1998
-------------------------
RIBOZYME PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
Colorado 0-27914 34-1697351
- ---------------------- ----------- ------------------
(State or other (Commission (IRS employer
jurisdiction of file number) identification no.)
incorporation
or organization)
2590 Wilderness Place, Boulder, Colorado 80301
- --------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (303) 449-6500
--------------
N/A
- --------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
-1-
5. Other Events
On November 23, 1998, Ribozyme Pharmaceuticals, Inc. (the "Company"),
finalized and entered into a Participation Agreement with Atugen Biotechnology
GmbH, a German company ("Atugen"), BB Bioventures L.P., and the following
individuals: Dr. Ralph E. Christoffersen, Mr. Lawrence E. Bullock, Dr. Nassim
Usman, Dr. James Thompson, Ms. Alene Holzman, Dr. Thomas H. Rossing, Dr. Jorg
Potzsch and Dr. Thomas Walther. The Company and Atugen also entered into the
following agreements related to the Participation Agreement: (1) License
Agreement, (2) Manufacturing and Supply Agreement and Sublicense and (3) Service
Agreement.
EXHIBITS
99.1 Participation Agreement dated August 24, 1998 among Atugen
Biotechnology GmbH, the Company, BB Bioventures L.P. and certain
founders
99.2 Amendment to Participation Agreement dated November 23, 1998 among
Atugen Biotechnology GmbH, the Company, BB Bioventures L.P. and
certain founders
99.3 License Agreement dated November 23, 1998 between Atugen Biotechnology
GmbH and the Company
99.4 Manufacturing and Supply Agreement and Sublicense dated November 23,
1998 between Atugen Biotechnology GmbH and the Company
99.5 Service Agreement dated November 23, 1998 between Atugen Biotechnology
GmbH and the Company
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
RIBOZYME PHARMACEUTICALS, INC.
DATE: June 9, 1999 By: /s/ DR. RALPH E. CHRISTOFFERSEN
------------ -----------------------------------------
Dr. Ralph E. Christoffersen, President
-3-